The OncoCyte leadership team has a proven track record of successfully developing and commercializing healthcare products and creating programs that result in better patient care.
OncoCyte Team




William Annett William Annett joined OncoCyte as Chief Executive Officer in June 2015. Mr. Annett’s diagnostics industry experience includes his service as CEO of BioFX Laboratories, Inc., an in vitro diagnostic company successfully sold to a large life sciences company. He founded and led Corra Life Sciences, a prenatal diagnostics company focused on diagnosis of the major diseases of pregnancy. Mr. Annett also founded a consumer products company, which became publicly traded on NASDAQ, during his six-year tenure as CEO, and then acquired. At Genentech, Mr. Annett led the Commercial Strategy group, managed large operational projects with several hundred team members, and directed the Project Finance function, which supported all pipeline products with more than 200 clinical trials. Most recently, Mr. Annett was a Managing Director at Accenture where he headed the West Coast Life Sciences practice with sales, marketing, and delivery responsibilities. His clients included most of the major biotech and pharmaceutical companies in the western United States. Mr. Annett is a member of the Board of Directors of the California Life Sciences Association. He holds an MBA from the Harvard Business School.




Lyssa Friedman Lyssa Friedman joined OncoCyte as a consultant in April 2014 and was named VP of Clinical and Regulatory Affairs in September 2015. Ms. Friedman started her career as a registered nurse specializing in oncology, and has led clinical research operations teams for more than 15 years. Ms. Friedman was a founding team member at Veracyte, where she executed a 49-site, 4000-subject clinical validation study that resulted in the launch of the Afirma® Gene Expression Classifier. She later oversaw clinical utility studies that contributed to positive coverage decision from the Centers for Medicare and Medicaid Services and major U.S private insurers. Ms. Friedman is an author of about a dozen peer-reviewed publications and is a frequent speaker on diagnostic development, clinical and regulatory affairs, and reimbursement. Ms. Friedman received her Masters in Public Administration from the University of San Francisco.




William Haack joined OncoCyte as Vice President of Market Access and Business Operations in June 2016. Mr. Haack has 20 years of life sciences experience, having leadership roles at Genentech, Genomic Health & Invitae. Mr. Haack had the great privilege of working on the teams at Genentech that launched Herceptin® and Rituxan® and was also involved in some of the early strategic work at Genentech in the area of molecular diagnostics. At Genomic Health, Mr. Haack lead both US and European Commercial Operations and Market Access teams during his 9 year tenure where he developed the department from infancy to over 120 people and nearly $300 million in annual global revenues. Mr. Haack also served as Adjunct Assistant Professor of Economics at Golden Gate University for 11 years where he taught micro and macro-economic theory. Mr. Haack received an MA in Economics at California State University, Hayward where he specialized in Econometrics.




Lyndal Hesterberg Lyndal Hesterberg Ph.D., joined OncoCyte as a consultant in 2015 and was named Vice President of Development in February of 2016. Dr. Hesterberg has worked as an industry consultant to medical and biotech companies providing counsel on clinical trial design, product development and corporate strategy. Previously, he was the CTO at Crescendo Biosciences until 2012 where he was responsible for clinical trial, laboratory operations, manufacturing and quality systems and helped bring to market Vectra DA. Before that, he was the president and CEO of Barofold, Inc., where he led the Company from product conception through its clinical stage. He also recruited a senior leadership team that developed a pipeline of proprietary drug candidates. Dr. Hesterberg also has been a Director of Research, EVP of Scientific affairs and Manager of Diagnostic Product Development. He received his Ph.D. in biochemistry from the University of St. Louis and a Bachelor of Sciences from the University of Illinois.




William Seltzer Mitch Levine joined OncoCyte as Chief Financial Officer in November 2017. Prior to joining OncoCyte, Mr. Levine was the Managing Partner of Kirby Cove Capital Advisors, which provides consulting services to international life sciences investment funds regarding collaboration and investment in US-based life sciences companies. In 2002, Mr. Levine founded Enable Capital Management and grew the firm into one of the largest and most respected brands globally in alternative finance. Its flagship fund, Enable Growth Partners, provided growth capital to more than 500 private and publicly traded companies, catalyzing transformative corporate innovation, job growth, and economic expansion in technology, life sciences, consumer products, and energy. Prior to founding Enable, Mr. Levine was a founding member of The Shemano Group, a leading San Francisco-based investment bank that focused on the capital needs of growth companies. He has also worked at Bear Stearns and Lehman Brothers. Mr. Levine received his BA from the University of California, Davis.




Kristine Mechem Kristine C. Mechem joined OncoCyte Corporation as Vice President of Marketing & Planning in August 2015. Dr. Mechem’s leadership and industry experience includes marketing, long range planning,  commercial opportunity assessments and analytic roles spanning from smaller early stage diagnostic companies such as Corra Life Sciences, to larger biopharma companies like Abbott and Genentech.

At Corra Life Sciences, a prenatal diagnostics company, she was a co-founder and in her business development and marketing role worked to secure co-development partners and to license IP from three prominent universities.  At Genentech, Dr. Mechem led the portfolio management and business planning process for a $400M product. Most recently, as a Director of Business Insights and Analytics at Abbott Diabetes Care, she led a team managing the business planning process and tracking key product performance.
Dr. Mechem holds a Ph.D. from the University of Chicago, and completed the Stanford Business School Executive Program in Strategy and Organization.




William Seltzer William K. Seltzer joined Oncocyte in September 2014 and in July of 2015 was appointed VP of Clinical Services. Dr. Seltzer is a board certified clinical molecular geneticist with 30 years commercial and academic experience in clinical diagnostic services and products development and commercialization, quality assurance and regulatory compliance. As an Associate Professor of Pediatrics at Colorado, he founded and directed the University’s DNA Diagnostic Laboratory. Dr. Seltzer has served as a member of the executive management team and/or as the Clinical Laboratory Director at a number of successful diagnostic companies including Athena Diagnostics, Veracyte and Counsyl. Over the course of his career, Dr. Seltzer has been responsible for the successful launch and oversight of clinical services for over 100 Laboratory Developed Tests (LDTs) in the fields of Neurology, Endocrinology, Nephrology, Molecular Cytology and Genetics. He has published more than 50 articles in peer-reviewed scientific journals and is co-inventor on patents for molecular diagnostics and methods. Dr. Seltzer received his Ph.D. in Pharmacology and Nutrition from the University of Southern California and completed his clinical fellowship in molecular genetics at the University of Colorado School of Medicine.


Michael G. Vicari


Michael G. Vicari joined OncoCyte in August 2017 as Vice President of Sales and brings 36 years of successful sales and marketing leadership within the healthcare industry, including the launch of several important diagnostic products. Before joining OncoCyte, he was Vice President of Sales and Marketing at Eurofins Scientific where he established two separate commercial organizations for EGL Labs and NTD Labs. Prior to Eurofins, he was Vice President of Sales for Sequenom, Inc., where he built the commercial organization, led the successful launch of the world’s first noninvasive prenatal test MaterniT21 and drove overall Sequenom sales from to over $150 million per year. Mr. Vicari was the Vice President of Sales and Marketing for Oncology/HIV at Monogram Biosciences before it was acquired by LabCorp and managed the launch of HerMark for breast cancer. Mike has served in senior commercial leadership roles at biotechs such as Genentech, Corixa Oncology, and MedImmune.